FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | |
|--------------------------|-----------|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | |
| Estimated average burden | | | | | | |
| hours per response: | 0.5 | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* CREDIT SUISSE FIRST BOSTON/ | | | | | | 2. Issuer Name and Ticker or Trading Symbol CYTOKINETICS INC [CYTK] | | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | |
|--|---|---|---------------|---|--|---|--------|-----------|---|---------------|--|---------|--|---|--|--|--|--------------------------------|------|---|--|
| (Last) | (First) |) (| Middle) | <u>'IN/</u> | - 3. | 3. Date of Earliest Transaction (Month/Day/Year) | | | | | | | | Director X 10% Owner Officer (give title Other (specify below) below) | | | | er (specify | | | |
| 11 MADISON AVENUE (Street) NEW YORK NY 10010 | | | | 4. | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | | |
| (City) | (State | | Zip) | n-Deri | vativ | ve Se | curit | ies Ac | auir | ed F |)isnose | d of | or Be | eneficia | ally (| Owned | | | | | |
| 1. Title of Security (Instr. 3) | | | 2. Tr Date | 2. Transaction 2A. Exe (Month/Day/Year) if an | | 2A. Deemed Execution Date, if any | | ate, T | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 and 5) | | | l (A) or | 5. Amount of Securities Beneficially Owned Following Reported | | Form: (D) or Indire | | rect | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | Code V | | Amount | | (A) or (D) | Price | | (Instr. 4) | | | | | | | |
| Common Stock | | 0.5 | /04/200 |)4 | | | | С | | 1,339,5 | 80 | A | \$0.00 | | 1,339,580 I | | I | See Footnote ⁽¹⁾ | | | |
| Common Stock - voting trust 0 | | | 05 | /04/200 |)4 | 1 | | | С | | 1,765,6 | 5,683 A | | \$0.00 | 1 | 1,765,683 | | I | | See Footnote ⁽²⁾⁽³⁾ | |
| | | | Table | | | | | | | | posed of converti | | | | wne | d | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | cise (Month/Day/Year) any 8) Securities Acquired (A Disposed of | | | ve Expiration Date Securities Underlying es (Month/Day/Year) Derivative Security (In 4) do f (D) | | | | | erlying | Derivative | | 9. Number of derivative Securities Beneficially Owned Following | | 10. Ownersi Form: Direct (I or Indire (I) (Instr | Beneficial Ownership ct (Instr. 4) | | | | | |
| | | | | C | ode | v | (A) | (D) | Date Exer | e rcisable | Expiration Date | Title | • | Amount Number Shares | | | Reported Transaction(s) (Instr. 4) | | | | |
| Series C Preferred Stock | (4) | 05/04/2004 | | | С | | | 4,210,52 | 7 | (5) | (6) | | Common Stock | 2,105 | ,263 | \$0.00 | | 0 | I | See Footnote ⁽³⁾ | |
| Series E Preferred Stock | (4) | 05/04/2004 | | | С | С | | 2,000,000 | 0 | (5) | (6) | | Common Stock | 1,000 | ,000 | \$0.00 | | 0 | I | See Footnote ⁽³⁾ | |
| 1. Name and Ad | ddress of F | Reporting Persor | * | | | | 1 | | | | | | | | | | | | | | |

| (First) | (Middle) | |
|---------|----------|----------|
| ENUE | | |
| | | |
| NY | 10010 | |
| (State) | (Zip) | |
| | NY | NY 10010 |

| PARTNERS | | BOSTON EQUITY |
|--|---|--------------------------------------|
| (Last) 11 MADISON A | (First) VENUE | (Middle) |
| Street) NEW YORK | NY | 10010 |
| (City) | (State) | (Zip) |
| CREDIT SU | ISSE FIRST | BOSTON EQUITY |
| (Last) 11 MADISON A | (First) VENUE | (Middle) |
| Street) NEW YORK | NY | 10010 |
| (City) | (State) | (Zip) |
| | rss of Reporting Pers | FUND 2000, L.P. |
| (Last) 11 MADISON A | (First) VENUE | (Middle) |
| (Street) NEW YORK | NY | 10010 |
| (City) | (State) | (Zip) |
| | ss of Reporting Per | |
| | | |
| (Last) | (First) VENUE | (Middle) |
| | VENUE | (Middle) |
| 11 MADISON A (Street) | VENUE | |
| (Street) NEW YORK (City) 1. Name and Addre | NY (State) | 10010 (Zip) son BOSTON U.S. |
| (Street) NEW YORK (City) 1. Name and Addre | NY (State) ss of Reporting Pers ISSE FIRST E ADVISORS | 10010 (Zip) son BOSTON U.S. |
| (Street) NEW YORK (City) 1. Name and Addre CREDIT SU EXECUTIVE | NY (State) ss of Reporting Pen ISSE FIRST ADVISORS (First) VENUE | 10010 (Zip) son* BOSTON U.S. i, L.P. |

| 1. Name and Addres CREDIT SUI ADVISORY I | SSE FIRS | ST BOSTON |
|--|------------------|-----------|
| (Last) 11 MADISON AV | (First) VENUE | (Middle) |
| (Street) NEW YORK | NY | 10010 |
| (City) | (State) | (Zip) |
| 1. Name and Address CREDIT SUI (BERMUDA) | SSE FIRS | |
| (Last) 11 MADISON AV | (First) VENUE | (Middle) |
| (Street) NEW YORK | NY | 10010 |
| (City) | (State) | (Zip) |
| 1. Name and Addres HEMISPHER PARTNERS | RE PRIVA | |
| (Last) HEMISPHERE H NINE CHURCH | | (Middle) |
| (Street) HAMILTON | D0 | HM11 |
| (City) | (State) | (Zip) |
| 1. Name and Addres HEMISPHEF PARTNERS | <u>RE PRIVA</u> | |
| (Last) HEMISPHERE H NINE CHURCH | | (Middle) |
| (Street) HAMILTON | D0 | HM11 |
| (City) | (State) | (Zip) |

Explanation of Responses:

- 1. See attachment A for footnotes.
- 2. See attachment A for footnotes.
- 3. See attachment A for footnotes.
- 4. 0.5
- 5. Immediately
- 6. The shares of preferred stock automatically converted into shares of common stock upon the closing of the issuer's initial public offering on May 4, 2004.

Remarks

(7) Kenneth J. Lohsen is signing as Attorney-in-Fact of Hemisphere Private Equity Partners, Ltd., the general partner of Credit Suisse First Boston Equity Partners, L.P., Credit Suisse First Boston Equity Partners (Bermuda), L.P. and Credit Suisse First Boston (Bermuda) Limited, the general partner of EMA Private Equity Fund 2000, L.P. and EMA Partners Fund 2000, L.P. Exhibit List Exhibit 99.1 - Joint Filer Information

| /s/ Ivy Dodes, Managing <u>Director</u> | 05/04/2004 |
|---|------------|
| /s/ Kenneth J. Lohsen. Attorney-in-Fact (7) | 05/04/2004 |
| /s/ Kenneth J. Lohsen. Attorney-in-Fact (7) | 05/04/2004 |
| /s/ Kenneth J. Lohsen, Vice President (8) | 05/04/2004 |
| /s/ Kenneth J. Lohsen, Vice President (8) | 05/04/2004 |
| /s/ Kenneth J. Lohsen, Attorney-in-Fact (7) | 05/04/2004 |
| /s/ Kenneth J. Lohsen, Controller | 05/04/2004 |
| /s/ Kenneth J. Lohsen, Vice President | 05/04/2004 |
| /s/ Kenneth J. Lohsen, Attorney-in-Fact | 05/04/2004 |
| /s/ Nigel Jeffrey Arkley & John Ivan Sutlic, Directors | 05/04/2004 |
| ** Signature of Reporting Person | Date |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Includes (a) 961,093 shares of common stock, par value \$0.001 per share (the "Shares"), of Cytokinetics, Incorporated held directly by Credit Suisse First Boston Private Equity, L.P. ("CSFB-EP"); (b) 268,650 Shares held directly by Credit Suisse First Boston Private Equity (Bermuda), L.P. ("CSFB Bermuda"); (c) 62,120 Shares held directly by EMA Private Equity Fund 2000, L.P. ("EMA Private"); (d) 46,862 Shares held directly by EMA Partners Fund 2000, L.P. ("EMA Partners"); and (e) 855 Shares held directly by Credit Suisse First Boston U.S. Executive Advisors, L.P. ("CSFB U.S.", and together with CSFB-EP, CSFB Bermuda, EMA Private and EMA Partners, the "CSFB Funds").
- (2) These Shares are held directly by Wells Fargo Bank, N.A. as voting trustee under a Voting Trust Agreement and includes (a) 1,266,803 Shares transferred to the voting trust by CSFB-EP; (b) 354,104 Shares transferred to the voting trust by CSFB Bermuda; (c) 81,880 Shares transferred to the voting trust by EMA Private; (d) 61,769 Shares transferred to the voting trust by EMA Partners; and (e) 1,127 Shares transferred to the voting trust by CSFB U.S.
- In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Form 4 is being filed by Credit Suisse First Boston (the "Bank"), a Swiss bank, on behalf of itself and its subsidiaries, to the extent that they constitute the Credit Suisse First Boston business unit (the "CSFB business unit") excluding Asset Management (as defined below) (the "Reporting Person"). The CSFB business unit is also comprised of an asset management business principally conducted under the brand name Credit Suisse Asset Management ("Asset Management"). The Reporting Person provides financial advisory and capital raising services, sales and trading for users and suppliers of capital around the world and invests in and manages private equity and venture capital funds. Asset Management provides asset management and investment advisory services to institutional, mutual fund and private investors worldwide. The address of the Bank's principal business and office is Uetlibergstrasse 231, P.O. Box 900, CH 8070 Zurich, Switzerland. The address of the Reporting Person's principal business and office in the United States is Eleven Madison Avenue, New York, New York 10010.

The CSFB Funds are the holders of the Shares. The principal business office of each of the CSFB Funds is 11 Madison Avenue, New York, New York 10010.

Pursuant to investment advisory agreements with CSFB-EP, CSFB Bermuda and CSFB U.S., Credit Suisse First Boston Advisory Partners, LLC, a Delaware limited partnership ("CSFB Advisory"), makes all investment decisions for these three CSFB Funds, including the decision to buy, sell or hold securities which comprise the assets of each of these entities. In addition, EMA Partners and EMA Private must invest in and dispose of its portfolio securities pro rata simultaneously with CSFB-EP pursuant to EMA Partners' and EMA Private's limited partnership agreements. Thus, CSFB Advisory may be deemed to be the beneficial owner of the Shares owned by the CSFB Funds.

CSFB Advisory is a wholly-owned subsidiary of the Bank. The investment committee of CSFB Advisory that oversees the investment decisions made for the CSFB Funds includes the employees of the Private Equity Division ("Private Equity Division") of the CSFB business unit. The Private Equity Division reports directly to a board of directors of CSFB LP Holding ("CSFBLP"), a wholly-owned subsidiary of Credit Suisse Group ("CSG"). Such board of directors is comprised in part of executive officers of CSG; both CSG and CSFBLP are corporations formed under the laws of Switzerland.

The ultimate parent company of the Bank is CSG. CSG is a global financial services company with two distinct business units. In addition to the CSFB business unit, CSG is comprised of the Credit Suisse Financial Services business unit (the "Credit Suisse Financial Services business unit"), which offers investment products, private banking and financial advisory services, including insurance and pension solutions, for private and corporate clients in Europe and other markets around the world. CSG's business address is Paradeplatz 8, P.O. Box 1, CH 8070 Zurich, Switzerland.

CSG, for purposes of the federal securities laws, may be deemed ultimately to control the Bank and the Reporting Person. CSG, its executive officers and directors, and its direct and indirect subsidiaries (including Asset Management and the Credit Suisse Financial Services business unit) may beneficially own the Shares, and such Shares are not reported in this form. CSG disclaims beneficial

ownership of Shares beneficially owned by its direct and indirect subsidiaries, including the Reporting Person. Each of Asset Management and the Credit Suisse Financial Services business unit disclaims beneficial ownership of Shares beneficially owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of Shares beneficially owned by CSG, Asset Management and the Credit Suisse Financial Services business unit.

Hemisphere Private Equity Partners, Ltd., a Bermuda company ("Hemisphere"), is the general partner of each of CSFB-EP, CSFB Bermuda and CSFB U.S. and, other than the investment activities for which CSFB Advisory is responsible, manages and controls the affairs of these three funds. Hemisphere is engaged in the business of acting as general partner to collective investment vehicles organized as limited partnerships. Hemisphere is controlled by Hemisphere Private Equity Partners Charitable Trust, a Bermuda trust ("Hemisphere Trust"), created for the purpose of acting as beneficial owner of Hemisphere. The Hemisphere Trust Company Limited is the trustee of Hemisphere Trust and is an indirect, wholly-owned subsidiary of Mutual Risk Management Ltd, a Bermuda company limited by shares. Mutual Risk Management Ltd. is an international risk management company and, to the extent it controls Hemisphere in its capacity as trustee of Hemisphere Trust, is the ultimate parent company of Hemisphere.

FORM 4 JOINT FILER INFORMATION

Name: Credit Suisse First Boston Equity Partners, L.P.

Address: 11 Madison Avenue, New York, NY 10010

Designated Filer: Credit Suisse First Boston

Issuer & Ticker Symbol: Cytokinetics, Incorporated ("CYTK")

Date of Event

Requiring Statement: May 4, 2004

CREDIT SUISSE FIRST BOSTON EQUITY PARTNERS, L.P.

By: Hemisphere Private Equity Partners, Ltd., its general partner

/s/ Kenneth J. Lohsen

Name: Kenneth J. Lohsen Title: Attorney-in-Fact

1

JOINT FILER INFORMATION (CONT'D)

Name: Credit Suisse First Boston Equity Partners

(Bermuda), L.P.

Address: 11 Madison Avenue, New York, NY 10010

Designated Filer: Credit Suisse First Boston

Issuer & Ticker Symbol: Cytokinetics, Incorporated ("CYTK")

Date of Event

Requiring Statement: May 4, 2004

CREDIT SUISSE FIRST BOSTON EQUITY PARTNERS (BERMUDA), L.P.

By: Hemisphere Private Equity Partners, Ltd., its general partner

/s/ Kenneth J. Lohsen

Name: Kenneth J. Lohsen Title: Attorney-in-Fact

JOINT FILER INFORMATION (CONT'D)

Name: EMA Private Equity Fund 2000, L.P.

Address: 11 Madison Avenue, New York, NY 10010

Designated Filer: Credit Suisse First Boston

Issuer & Ticker Symbol: Cytokinetics, Incorporated ("CYTK")

Date of Event

Requiring Statement: May 4, 2004

EMA PRIVATE EQUITY FUND 2000, L.P.

By: Credit Suisse First Boston (Bermuda) Limited, its general partner

/s/ Kenneth J. Lohsen

Name: Kenneth J. Lohsen Title: Vice President

3

JOINT FILER INFORMATION (CONT'D)

Name: EMA Partners Fund 2000, L.P.

Address: 11 Madison Avenue, New York, NY 10010

Designated Filer: Credit Suisse First Boston

Issuer & Ticker Symbol: Cytokinetics, Incorporated ("CYTK")

Date of Event

Requiring Statement: May 4, 2004

EMA PARTNERS FUND 2000, L.P.

By: Credit Suisse First Boston (Bermuda) Limited, its general partner

/s/ Kenneth J. Lohsen

Name: Kenneth J. Lohsen Title: Vice President

4

JOINT FILER INFORMATION (CONT'D)

Credit Suisse First Boston U.S. Executive

Advisors, L.P.

Name:

Address: 11 Madison Avenue, New York, NY 10010

Designated Filer: Credit Suisse First Boston

Issuer & Ticker Symbol: Cytokinetics, Incorporated ("CYTK")

Date of Event

Requiring Statement: May 4, 2004

CREDIT SUISSE FIRST BOSTON U.S. EXECUTIVE ADVISORS, L.P. $\,$

By: Hemisphere Private Equity Partners, Ltd., its general partner

/s/ Kenneth J. Lohsen

Name: Kenneth J. Lohsen Title: Attorney-in-Fact

5

JOINT FILER INFORMATION (CONT'D)

Name: Credit Suisse First Boston Advisory Partners, LLC

Address: 11 Madison Avenue, New York, NY 10010

Designated Filer: Credit Suisse First Boston

Issuer & Ticker Symbol: Cytokinetics, Incorporated ("CYTK")

Date of Event

Requiring Statement: May 4, 2004

CREDIT SUISSE FIRST BOSTON ADVISORY

PARTNERS, LLC

/s/ Kenneth J. Lohsen

Name: Kenneth J. Lohsen

Title: Controller

6

JOINT FILER INFORMATION (CONT'D)

Name: Credit Suisse First Boston (Bermuda) Limited

Address: 11 Madison Avenue, New York, NY 10010

Designated Filer: Credit Suisse First Boston

Issuer & Ticker Symbol: Cytokinetics, Incorporated ("CYTK")

Date of Event

Requiring Statement: May 4, 2004

CREDIT SUISSE FIRST BOSTON (BERMUDA)

LIMITED

/s/ Kenneth J. Lohsen

Name: Kenneth J. Lohsen Title: Vice President

JOINT FILER INFORMATION (CONT'D)

Hemisphere Private Equity Partners, Ltd. Name:

Address: Hemisphere House, Nine Church Street, Hamilton HM11,

Hamilton, Bermuda

Designated Filer: Credit Suisse First Boston

Issuer & Ticker Symbol: Cytokinetics, Incorporated ("CYTK")

Date of Event

May 4, 2004 Requiring Statement:

HEMISPHERE PRIVATE EOUITY

PARTNERS, LTD.

/s/ Kenneth J. Lohsen

Name: Kenneth J. Lohsen Title: Attorney-in-Fact

7

JOINT FILER INFORMATION (CONT'D)

Name: Hemisphere Private Equity Partners Charitable Trust

Address: Hemisphere House, Nine Church Street, Hamilton HM11,

Hamilton, Bermuda

Designated Filer: Credit Suisse First Boston

Cytokinetics, Incorporated ("CYTK") Issuer & Ticker Symbol:

Date of Event

Requiring Statement: May 4, 2004

> HEMISPHERE PRIVATE EQUITY PARTNERS CHARITABLE TRUST

By: Hemisphere Trust Company Limited in its capacity as trustee

/s/ Nigel Jeffrey Arkley & John Ivan Sutlic

Name: Nigel Jeffrey Arkley & John Ivan Sutlic Title: Directors